Search clinical trials for: Insulin Glargine (U100)

Total 4962 results

Sanofi

Completed

32 Week, Open, Randomized, 2 Way Cross Over Multicentre Trial to Compare Safety & Efficacy of Combination of HOE901 Insulin Analogue Once Daily at Bedtime + Lispro Insulin Before Meals vs NPH Insulin (Twice a Day) + Regular in Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1
Novo Nordisk A/S

Completed

Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, France, Sweden, Poland, Turkey, Korea, Republic of, India, South Africa
Ain Shams University

Recruiting

Outcome of Glargine Insulin in Renal Impairment Patients With Diabetic Ketoacidosis

Chronic Kidney Diseases

Egypt
Sanofi

Completed

Insulin Glargine in Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1
Sanofi

Completed

Insulin Glargine in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus
Sanofi

Completed

Extension to Study HMR1964A/3011 in Belgium

Diabetes Mellitus

Belgium
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 1)

Diabetes Mellitus, Type 2

United States, Croatia, India, Israel, Italy, Japan, Mexico, Poland, Puerto Rico, Russian Federation, Slovakia, Spain, United Kingdom
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Completed

A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico, Spain, Denmark, Austria, Belgium, Serbia, Germany, Slovenia, Canada, France, Finland, Former Serbia and Montenegro, Czech Republic, Norway
Novo Nordisk A/S

Completed

A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Delivery Systems

Denmark
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI); Sanofi

Withdrawn

Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia

Hyperglycemia | Leukemia

United States
Sanofi

Completed

Lantus Versus Levemir Treat-To-Target (L2T3)

Diabetes Mellitus, Type 2

Korea, Republic of, Russian Federation, Spain, Denmark, Canada, Germany, Ireland, Portugal, Australia, India, Turkey, Netherlands, Sweden, United Kingdom, Finland, Switzerland, Romania, Brazil, Serbia, Taiwan
Newcastle University
Sanofi; Medtronic; Newcastle-upon-Tyne Hospitals NHS Trust; Newcastle Primary Care...

Completed

Prevention of Severe Hypoglycemia in Type 1 Diabetes

Type 1 Diabetes Mellitus

United Kingdom
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (SWITCH 1)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Puerto Rico
Novo Nordisk A/S

Completed

Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes (EFFICACY)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico, Argentina, Thailand, India, Korea, Republic of
ikfe-CRO GmbH
IKFE Institute for Clinical Research and Development

Unknown

Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use

Insulin-requiring Type 2 Diabetes Mellitus

Germany
Emory University
Sanofi

Completed

Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)

Diabetic Ketoacidosis

United States
Shenzhen Second People's Hospital

Unknown

Study on the Feasibility of Community Doctors Guided by Specialists to Use Basic Insulin

Type 2 Diabetes
Eli Lilly and Company

Completed

A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus (IMAGINE 5)

Diabetes Mellitus, Type 2

United States, Germany, Israel, Czechia, Spain, Russian Federation, Romania, Puerto Rico, Greece
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Germany, United Kingdom, Austria, Belgium, France, Ireland
Sanofi

Completed

Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

Diabetes Mellitus, Type 2

India, United States, Thailand, Japan, Germany, Turkey, Hungary, Malaysia, Poland, South Africa, Czechia, Italy, France, Slovenia
Emory University
Sanofi; University of Miami

Completed

Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes

Hyperglycemia | Diabetes

United States
Eli Lilly and Company

Completed

A Study for Patients With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States, Israel
Ruhr University of Bochum

Completed

Chronic Reduction of Fasting Glycaemia With Insulin Glargine Improves First and Second Phase Insulin Secretion in Patients With Type 2 Diabetes

Type 2 Diabetes

Germany
Sanofi

Completed

Insulin Analogue With Continuous Glucose Monitoring System (CGMS) Measurement (SAFIR)

Diabetes Mellitus Type 2
Sanofi

Completed

Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2) (COBIN 2)

Diabetes Mellitus, Type 2

Czech Republic
Novo Nordisk A/S

Completed

A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Diabetes Care Center

Unknown

A Study of the Rules for Insulin Dosing in Patients Using Multiple Daily Injections

Diabetes Mellitus Type 1

United States
Pfizer

Completed

A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

United States, France, United Kingdom, Russian Federation, Germany, South Africa
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, United Kingdom, Belgium, Norway, Germany, Greece
Novo Nordisk A/S

Completed

Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Puerto Rico, Spain, Russian Federation, Turkey, Austria, India, Korea, Republic of
Baylor College of Medicine

Completed

Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes

Type 1 Diabetes

United States
Sanofi

Completed

LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Israel
Sanofi

Completed

ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus.

Diabetes Mellitus, Type 2

Italy
HaEmek Medical Center, Israel

Completed

Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical Wards

Diabetes Mellitus Type 2
Novo Nordisk A/S

Completed

Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany, Austria, South Africa
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Sweden, Finland, France, Norway
Sanofi

Completed

Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic Control (LANTIT)

Diabetes Mellitus, Type 2

Turkey
Sanofi

Completed

Lantus Effect on Myocardial Glucose Metabolism in T2

Diabetes Mellitus, Type 2

Italy
Sanofi

Completed

Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

United States, Canada
Sanofi

Completed

The Incidence of Hypoglycemia in Insulin Glargine-Treated Subjects With Diabetes Mellitus Upon Switching Between Bedtime and Morning Dosing

Diabetes Mellitus

Mexico
Sanofi

Completed

LANCGMS - Lantus Continuous Glucose Monitoring Subcutaneous

Diabetes Mellitus

Czech Republic

3

Subscribe